June 19, 2017 07:51 AM EDT

Novartis wins another biosimilar round with an OK for its Rituxan copycat

John Carroll

Editor & Founder

Novartis just racked up its fourth new biosimilar approval in Europe, this time gaining a thumbs up for its knockoff of Roche megablockbuster Rituxan …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Novartis wins another biosimilar round with an OK for its Rituxan copycat

John Carroll

Editor & Founder

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Why did Eli Lilly ask a patient on a compounded GLP-1 drug for their medical information?

FDA OKs the first-ever self-administered vaccine, for flu

The drug lobby's lawsuit against the IRA finds a sign of life after appeals court ruling

Biotech VC firm outlines plans for $100M fund

FTC to sue major PBMs over insulin rebates, claiming they inflated patient cost

Breaking down silos with a new quantitative approach to drug development

No­var­tis wins an­oth­er biosim­i­lar round with an OK for its Rit­ux­an copy­cat

Editor & Founder

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Novartis wins another biosimilar round with an OK for its Rituxan copycat